Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice
暂无分享,去创建一个
Taane G. Clark | Julian Parkhill | Roland Rad | Thomas R. Connor | Harry J. Flint | Gordon Dougan | Trevor D. Lawley | Simon Clare | Cordelia Brandt | T. Clark | R. Rad | S. Clare | G. Dougan | J. Parkhill | H. Flint | A. Walker | S. Duncan | M. Stares | D. Goulding | D. Pickard | T. Connor | T. Lawley | C. Raisen | David Goulding | Sylvia H. Duncan | Alan W. Walker | Mark D. Stares | Derek J. Pickard | Claire Raisen | Fernanda Schreiber | Laura J. Deakin | F. Schreiber | C. Brandt | Laura J Deakin | Cordelia Brandt | T. Clark | A. Walker | Mark D. Stares
[1] G. Macfarlane,et al. Regulation of short-chain fatty acid production , 2003, Proceedings of the Nutrition Society.
[2] N. Salzman,et al. Prolonged Impact of Antibiotics on Intestinal Microbial Ecology and Susceptibility to Enteric Salmonella Infection , 2009, Infection and Immunity.
[3] Stuart Johnson,et al. An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.
[4] C. Pothoulakis,et al. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[5] A. Richardson,et al. Simultaneous determination of volatile and non‐volatile acidic fermentation products of anaerobes by capillary gas chromatography , 1989 .
[6] Jeffrey D Goldsmith,et al. A mouse model of Clostridium difficile-associated disease. , 2008, Gastroenterology.
[7] M. Woolhouse,et al. Super-shedding and the link between human infection and livestock carriage of Escherichia coli O157 , 2008, Nature Reviews Microbiology.
[8] O. Dekkers,et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. , 2012, The Journal of antimicrobial chemotherapy.
[9] Patrick D Schloss,et al. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection , 2011, Gut microbes.
[10] Andries J. van Tonder,et al. Evolutionary dynamics of Clostridium difficile over short and long time scales , 2010, Proceedings of the National Academy of Sciences.
[11] Ken Dewar,et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.
[12] L. Mcfarland. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. , 2009, Anaerobe.
[13] Harald Meier,et al. 46. ARB: A Software Environment for Sequence Data , 2011 .
[14] E. Kuijper,et al. Clostridium difficile infection in Europe: a hospital-based survey , 2011, The Lancet.
[15] J. Parkhill,et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota , 2011, The ISME Journal.
[16] D. Gerding. Clostridium difficile 30 years on: what has, or has not, changed and why? , 2009, International journal of antimicrobial agents.
[17] D. Gerding,et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] N. Fairweather,et al. The Clostridium difficile spo0A Gene Is a Persistence and Transmission Factor , 2012, Infection and Immunity.
[19] Paramvir S. Dehal,et al. FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments , 2010, PloS one.
[20] E. Birney,et al. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. , 2008, Genome research.
[21] M. Sakamoto,et al. Reclassification of Bacteroides distasonis, Bacteroides goldsteinii and Bacteroides merdae as Parabacteroides distasonis gen. nov., comb. nov., Parabacteroides goldsteinii comb. nov. and Parabacteroides merdae comb. nov. , 2006, International journal of systematic and evolutionary microbiology.
[22] C. Donskey,et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Mathias J Friedrich,et al. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. , 2006, Gastroenterology.
[24] T. Borody,et al. Fecal microbiota transplantation and emerging applications , 2012, Nature Reviews Gastroenterology &Hepatology.
[25] M. Tvede,et al. Bacteriotherapy for chronic relapsing Clostridium difficile in six patients , 1989 .
[26] J. Bartlett,et al. Clinical practice. Antibiotic-associated diarrhea. , 2002, New England Journal of Medicine.
[27] Y. Benjamini,et al. More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.
[28] A. Tatem,et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread , 2010, The Lancet Infectious Diseases.
[29] N. Fairweather,et al. Antibiotic Treatment of Clostridium difficile Carrier Mice Triggers a Supershedder State, Spore-Mediated Transmission, and Severe Disease in Immunocompromised Hosts , 2009, Infection and Immunity.
[30] M. Quail,et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium , 2009, Genome Biology.
[31] J. Wehland,et al. Clostridium difficile Toxin CDT Induces Formation of Microtubule-Based Protrusions and Increases Adherence of Bacteria , 2009, PLoS pathogens.
[32] J. Bakken. Fecal bacteriotherapy for recurrent Clostridium difficile infection. , 2009, Anaerobe.
[33] Julian Parkhill,et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome , 2006, Nature Genetics.
[34] M. Wilcox,et al. The potential for airborne dispersal of Clostridium difficile from symptomatic patients. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] S. Tzipori,et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. , 2012, The Journal of infectious diseases.
[36] S. Roos,et al. Lactobacillus reuteri prevents colitis by reducing P-selectin-associated leukocyte- and platelet-endothelial cell interactions. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[37] T. Borody,et al. Bacteriotherapy Using Fecal Flora: Toying With Human Motions , 2004, Journal of clinical gastroenterology.
[38] J. Bakken,et al. Treating Clostridium difficile infection with fecal microbiota transplantation. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[39] D. Relman,et al. Host Transmission of Salmonella enterica Serovar Typhimurium Is Controlled by Virulence Factors and Indigenous Intestinal Microbiota , 2007, Infection and Immunity.
[40] Martin Hartmann,et al. Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities , 2009, Applied and Environmental Microbiology.
[41] R. D. de Souza,et al. Colonic Health: Fermentation and Short Chain Fatty Acids , 2006, Journal of clinical gastroenterology.
[42] D. Gerding,et al. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. , 2009, Gastroenterology.
[43] J. Rask-Madsen,et al. BACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS , 1989, The Lancet.
[44] B. Finlay,et al. Antibiotic-Induced Perturbations of the Intestinal Microbiota Alter Host Susceptibility to Enteric Infection , 2008, Infection and Immunity.
[45] James R. Cole,et al. The Ribosomal Database Project: improved alignments and new tools for rRNA analysis , 2008, Nucleic Acids Res..
[46] A. Sarah Walker,et al. Characterisation of Clostridium difficile Hospital Ward–Based Transmission Using Extensive Epidemiological Data and Molecular Typing , 2012, PLoS medicine.
[47] E. van Nood,et al. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[48] D. Gerding,et al. Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. , 2009, Anaerobe.
[49] Peer Bork,et al. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation , 2007, Bioinform..
[50] T. Louie,et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. , 2010, Microbiology.
[51] D. Relman,et al. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation , 2010, Proceedings of the National Academy of Sciences.
[52] T. Clark,et al. Use of Purified Clostridium difficile Spores To Facilitate Evaluation of Health Care Disinfection Regimens , 2010, Applied and Environmental Microbiology.
[53] J. Sirard,et al. The Microbiota Mediates Pathogen Clearance from the Gut Lumen after Non-Typhoidal Salmonella Diarrhea , 2010, PLoS pathogens.
[54] R. Seaton,et al. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. , 2009, QJM : monthly journal of the Association of Physicians.
[55] Hilary G. Morrison,et al. Reproducible Community Dynamics of the Gastrointestinal Microbiota following Antibiotic Perturbation , 2009, Infection and Immunity.
[56] D. Antonopoulos,et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. , 2008, The Journal of infectious diseases.
[57] A. Viale,et al. Profound Alterations of Intestinal Microbiota following a Single Dose of Clindamycin Results in Sustained Susceptibility to Clostridium difficile-Induced Colitis , 2011, Infection and Immunity.
[58] J. Ballard,et al. Variations in TcdB Activity and the Hypervirulence of Emerging Strains of Clostridium difficile , 2010, PLoS pathogens.
[59] J. Brazier. Clostridium difficile: from obscurity to superbug , 2008, British journal of biomedical science.
[60] S. Mazmanian,et al. A microbial symbiosis factor prevents intestinal inflammatory disease , 2008, Nature.
[61] G. Dougan,et al. Salmonella enterica Serovar Typhimurium Exploits Inflammation to Compete with the Intestinal Microbiota , 2007, PLoS biology.
[62] S. Clare,et al. Proteomic and Genomic Characterization of Highly Infectious Clostridium difficile 630 Spores , 2009, Journal of bacteriology.
[63] K. Schleifer,et al. ARB: a software environment for sequence data. , 2004, Nucleic acids research.
[64] Barak A. Cohen,et al. Phylogeny based discovery of regulatory elements , 2006, BMC Bioinformatics.
[65] Pamela Sears,et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.
[66] Steven Salzberg,et al. Identifying bacterial genes and endosymbiont DNA with Glimmer , 2007, Bioinform..
[67] Courtney J. Robinson,et al. From Structure to Function: the Ecology of Host-Associated Microbial Communities , 2010, Microbiology and Molecular Biology Reviews.
[68] Jon Brazier,et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe , 2005, The Lancet.
[69] J. Handelsman,et al. Introducing DOTUR, a Computer Program for Defining Operational Taxonomic Units and Estimating Species Richness , 2005, Applied and Environmental Microbiology.
[70] D. Gerding. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.